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Backgroulld. We have demonstrated that donor cell 
chimerism is associated with a lower incidence of oblit-
erative bronchiolitis (OB) in lung recipients, and that 
donor chimerism is augmented by the infusion of donor 
bone marrow (BM). We herein report the intermediate 
results of a trial combining the infusion of donor BM and 
lung transplantation. 
Methods. Clinical and in vitro data of 26 lung recipi-
ents receiving concurrent infusion of donor bone marrow 
(3.0 to 6.0 x 1M~ cellsfkg) were compared with those of 13 
patients receiving lung transplant alone. 
Results. Patient survival and freedom from acute rejec-
tion were similar between groups. Of the patients whose 
W e and others have reported that a low level of bone-marrow derived cells was detectable in the 
peripheral blood and tissues of long-term survivors of 
liver [1], kidney [2], heart [3], lung, and heart-lung [4] 
allografts. This phenomenon of donor cell chimerism, 
which occurs by seeding of the host's tissues with cells 
from the graft [5], was associated with a lower incidence 
of chronic rejection in lung recipients [41. To augment 
donor cell chimerism, in order to modulate the response 
of the recipient to the allograft, we initiated a prospective 
trial combining the infusion of donor bone marrow and 
lung transplantation. Reported herein is the intermediate 
outcome of this clinical trial. 
Patients and Methods 
This study was approved by the Institutional Review 
Board of the University of Pittsburgh on July 14,1993, and 
informed consent was obtained from all patients. Be-
tween September 1993 and July 1998, 26 adult patients 
received combined infusion of donor bone marrow and 
lung transplant. In addition, unavailability of consent to 
retrieve donor bone marrow has resulted in the accrual of 
13 contemporaneous control patients, who received lung 
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graft survived greater than 4 months, 5% (I of 22) of BM 
and 33% (4 of 12) of control patients, developed histo-
logic evidence of OB (I' = 0.04). A higher proportion (but 
not statistically significant) of BM recipients (7 of 10, 
70%) exhibited donor-specific hyporeactivity by mixed 
lymphocyte reaction assays as compared with the con-
trols (2 of 7, 28°'0). 
Conclusions. Infusion of donor BM at the time of lung 
transplantation is safe, and is associated with recipients' 
immune modulation and a lower rate of obliterative 
bronchiolitis. 
(Ann Thorac Surg 2000;69:345-50) 
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transplant alone. These patients, all undergoing primary 
lung transplantation, were not conditioned by myeloab-
lative or myeloreductive regimen before transplantation. 
BOllt' Marrow Preparation and Infusion 
Donor bone marrow cells were isolated from thoraco-
lumbar vertebrae as described [6]. Unmodified bone 
marrow cells, at a dose of 3.0 to 6.0 x 1M~ cellsfkg of 
recipient's body weight, were resuspended in 200 mL of 
the suspension medium, and infused into the patient 
within 2 hours after preparation, and between 6 to 10 
hours after revascularization of the heart. 
Immunosuppression 
Immunosuppression consisted of tacrolimus (FK506, Pro-
graf; Fujisawa USA, Deerfield, IL) and steroids, as previ-
ously described. During the first postoperative month, 
the dose of tacrolimus was targeted to maintain whole 
blood trough levels of 15 to 20 ngfmL Depending on the 
side effects and history of rejection, tacrolimus dose was 
gradually reduced to achieve levels of 10 to 15 ngfmL. 
Methylprednisolone (500 mg; Upjohn Pharmaceuticals, 
Kalamazoo, MI) was given intraoperatively before revas-
cularization of the lung graft. Subsequently, a short 
course of steroid cycle was initiated on postoperative day 
(POD) 0, starting with 200 mg of methylprednisolone per 
day administered intravenously in 4 divided doses. The 
dose of methylprednisolone was tapered by a daily 
decrement of 40 mg/day and converted to oral pred-
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nisone, (20 mg/day) on POD 5. Systematic reduction of 
prednisone dose (by 2.5 to 5 mg decrements) was initi-
ated in all patients 3 months after transplantation, if there 
was no significa nt rejection by transbronchial biopsy. 
Azathioprine (2 mg/kg/daYi Imurani Burroughs Well-
come, Research Triangle Park, NO of mycophenolate 
mofetil (2 g/daYi Cell-Cepti Roche Laboratories, Basel, 
Switzerland) was added if there was recurrent rejection, 
or when renal dysfunction (serum creatinine > 2.0 mgt 
dL) necessitated a reduction of tacrolimus dose. 
Monitoring and Treatment of Rejection 
Surveillance bronchoscopy and transbronchial biopsy 
was performed in all patients between POD 14 and 21, 
unless clinical criteria warranted earlier intervention. 
Subsequently, surveillance biopsies were obtained every 
3 months in the first year, and every fourth month in the 
second year. Thereafter, the biopsy schedule was dic-
tated by clinical symptoms, and by results of pulmonary 
function tests. Follow-up biopsies are generally per-
formed 3 to 4 weeks following treatment of rejection, or 
after cytomegalovirus pneumonia. Acute rejection was 
defined by histologic criteria [7], with grade II or higher 
considered significant, and required treatment. Previ-
ously described criteria were used for the histological 
diagnosis and clinical staging of obliterative bronchiolitis 
(OB) [8, 9]. The histological diagnosis for OB was made in 
a blinded fashioned. Acute rejection was treated with 
pulses of methylprednisolone (1 g/day for 3 consecutive 
days). Cytolytic therapy was used when the rejection was 
refractory to 2 to 3 courses of pulse steroids. 
Detection of Chimerism 
After transplantation, recipients were typed for donor 
chimerism in peripheral blood leukocytes by flow cytom-
etry, as previously reported [6]. Blood samples (20 mL) 
from the patients were obtained on day 0 (time of 
transplantation), dav 15, day 30, day 60, a~d then everv 
other month during'the first-2 years ~fter transplantatio~I 
for the detection of donor cells. After staining with the 
appropriate antibody against donor MHC class I anti-
gens, single-color fluorescence-activated cell sorting 
(FACS) analysis was performed to identify donor cells, 
using an EPICS Elite Flow Cytometer (Coulter Corp, 
Hialeah, FL). Fifty thousand events were collected per 
sample for analyses. Values of circulating donor cells of 
less than 0.5% were considered not quantifiable. 
Jmmllne Monitorillg 
Pretransplant and serial postlransplant (every other 
month) monitoring of recipients' immune status was 
carried out by evaluating the proliferative responses of 
their peripheral blood leukocytes to mitogens (con-
canavalin A, phytohemagglutinin), and mixed leukocvte 
reactions (MLR), as previously described [10]. Recipients' 
donor-specific MLR responses (D) at various times post-
transplantation were compared to the recipients' pre-
transplant donor-specific responses, and to responses to 
cells from third party controls (TP). Donor-specific reac-
tivity was classified according to the previously described 
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criteria [10]. Briefly, donor-specific hyporeactivity (cate-
gory I) was defined as at least a 70% decrease in post-
transplant versus pretransplant donor-specific MLR re-
sponses, while maintaining reactivity to both third party 
stimulators (D/TP ratio < 40%) and to mitogens (> 50·. 
of pretransplant responses). Donor-specific intermediate 
reactivity (category II) was designated when there was a 
40.1• to 70% inhibition of antidonor activity with retention 
of third party responsiveness, whereas reactive (category 
Ul) meant that there was minimal or no decline in 
donor-specific nonreactivity. Suppression (categorv IV) 
connoted a nonspecific diminished proliferative response 
to mitogens as well as to alloantigens. 
Statistical Analysis 
Continuous variables were expressed as mean :: stan-
dard deviation (SO), and compared using t-test or Mann-
Whitney test when appropriate. Differences· in propor-
tions were compared using the y or Fisher exact test. 
Survival and freedom from acute rejection were esti-
mated by Kaplan-Meier method, and compared using 
the log-rank test. A p value less than 0.05 was considered 
statistically significant. A software package (CSS Statis-
tica, Release 4.5; Statsoft, Tulsa, OK) was used for statis-
tical analyses. 
Results 
Clinical COllrse and Patient Sun'ival 
The infusion of donor bone marrow was well tolerated. 
None of the 26 BM recipients developed graft-versus-
host disease or had complications related to the infusion 
of donor bone marrow. The 1 and 3-year actuarial patient 
survival rates were TT°D~I 77"" for the controls, and 81 "" 
and 77°. for the BM group, respectively (p = 0.9). Seven 
patients in the BM group died from bacterial infection 
(n = 2), OB (n = 1), fungal infection (n = 1), renal failure 
(n = 1), cerebral bleeding (n = 1), and cardiac arrest (n = 
1). In the control group there were 5 deaths, and the 
causes include bacterial infection (n = n OB (n = 1), 
respiratory failure (n = 1), pancreatitis (n = 1), and 
multisystem organ failure (n = 1). 
Acute Rejection alld Obliterative Bronchiolitis 
The linearized rejection rates (episode per patient) dur-
ing the first 6 months after transplantation were 2.6 = 0.3 
and 2.0 :: 0.2 in the BM and control groups, respecti\'e!v 
(p = 0.5). Only patients who survived for at least 6 
months after transplantation were included in the calcu-
lation of the linearized rejection rate. Freedom from acute 
rejection at 100 days after transplantation (by Kaplan-
Meier method) was 25.0·0 in the bone marrow group and 
8.0"0 in the control (p = 0.9). 
Of the patients whose graft survival time was greater 
than 4 months, 5% (1 of 22) bone marrow patients and 
33"0 (4 of 12) control patients developed histological 
evidence ofOB on transbronchial biopsy(p = 0.04). Two 
patients in the bone marrow group (2 of 22) and 2 in the 
control group (2 of 12) have clinical bronchiolitis obliter-
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Tahle 1. Pre7:'I1/CIICC of PatllOlogical Oblitcmtipc 
Bronchiolitis and Clinical Bronchio/itis Obliterans Syndrome 
Patient Group Bpne Marrow 
Surviving .. months 22 
With OB 1 (5",,) 
With BOS 2 (9"0) 
With either OB or B05 2 (9",,) 
'Two-tailed, F),her l'xact test. 
BOS ~ bronchiolitis obliterans s\'nJrome; 
bronEhio!ih~K 
Control 
12 
4 (33"0) 
2(17",,) 
:; (42',,) 
06 
P 
\' alue" 
0.04 
0.60 
0.07 
obliterative 
ans svndrome (BOS), and one in each group had both OB 
and BOS. In other words, the proportion of patients with 
either OB or BOS in the bone marrow and control groups 
was 9°. (2 of 22) and 42°,,, (5 of 12), respectively (p = 0.07; 
Table 1). 
Immunosupprcssion Profilcs 
At last follow-up, or at the time of death, the dose and 
level of tacrolimus, the dose of prednisone, and the 
number of patienb on prednisone were similar between 
the tv.·o groups (Table 2), Howe\,er, the number of pa-
tients requiring a third drug (either azathioprine or 
mycophenolate mofetil), because of persistent rejection 
or renal dysfunction (defined as having a serum cre-
atine > 2 mg/dL), is higher in the control group (77°" [10 
of 13) versus 17% [4 of 23], P = 0.0009). 
DOllor Chimerism 
Detection of donor cells was feasible (when appropriate 
antibody to donor HLA antigens were available) in 13 BM 
patients and 8 controls. The numbers are too small for 
meaningful statistical analvses, however there is trend 
toward higher level of donor chimerism in the peripheral 
blood of BM patients, as compared ~;th the controls (Fig 
1, 2). In both groups the level of donor chimerism is 
higher in the early postoperative period, and decreases 
with time. However, the chimerism persists much longer 
in the BM group than in the control. None of the control 
group had detectable level of donor chimerism at 1 vear, 
whereas 63 % (5 of 8) of BM recipients still had detectable 
Table 2. Immunosuppression Profilesa of Controls and Lllng 
Recipients Rec/'iping Bone Marrow ff~fusioll 
Bone 
Immunosuppression Marrow Control 
FK dose (mg) 10.8 ::: 7.1 8.2::: 3.6 
FK level (ng/mLl 13.3 ::: 5.3 12.0::: 3.9 
Prednisone dose (mg) 8.3 :: 4.3 6.8 ::: 2.3 
Patients on prednisone 18/23 (78%) 12113 (92%) 
Patients on third drug 4/23 (17%) 10/13 (77%)h 
• Onl" in patients survi\'ing more than 1 month after transplantation. 
b p ~ 0.0009, two-tailed, Fisher exact test. 
FK = tacrolimus, 
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Table 3. Demographics of Lung Recipiellts 
Bone 
\'ariables Marrow Control 
n 26 13 
Recipient age (v) 48.1 :: 11.0 50.23 :: 8.0 
Donor age (y) 25.3 :: 10.9 30.9 :: 10.1 
Sex (M:F) 18:8 3:10" 
T\'pe of transplant 
Single lung 19.0 9.0 
Double lung 7.0 3.0 
Heart lung 2.0 1.0 
Donor ischemic time (min) 235.1 ::: 76.2 279.6 :: 51.0 
MHC mismatch 4.8 :: 1.0 4.9 :: 1.0 
Follow-up duration (days) 729 :: 475 841 :: 445 
• I' -- 0.05, Fisher's exact test. 
MHC ~ major histocompatibility complex, 
le\'el of chimerism (bv flow cytometry) more than 1 vear 
after transplantation." .. . 
In Fitro Immune Testing 
In vitro immune testing was possible only when donor 
splenocvtes were available. Recipients' donor-specific, 
mixed leukocyte responses to donor antigens at various 
times posttransplantation were compared with the recip-
ient's pretransplant responses. Using previously de-
scribed criteria [10) we found that, a higher proportion 
(but not statistically Significant, " = 0.15) of BM recipi-
ents (7 of 10; 70°'0) exhibit donor-specific hyporeactivity 
as compared with the control group (2 of 7; 28°(0). Figure 
3 depicts the profile of a mixed leukocyte response of a 
BM-lung recipient who demonstrated donor-specific 
hyporesponsiveness. 
Comment 
The use of bone marrow-derived cells (splenocytes) to 
achieve donor-specific transplantation tolerance in neo-
natal mice was first reported by Billingham, Brent, and 
Medawar Ill). Subsequently, chimerism and donor-
specific transplantation toler~nce was achieved in adult 
animals by preconditioning the host with different regi-
mens which include, among others, total body irradiation 
[12), total lymphoid irradiation [13], and the use antilym-
phocyte globulin [14). The clinical use of donor bone 
marrow to prolong the survival of organ allograft was 
first attempted in kidney transplant recipients. Monaco 
and colleagues [151 were the first to report the use of 
antilymphocyte globulin induction and delaved (25 davs 
after organ transplantation) donor bone mar~ow infusi~n 
in a kidney transplant recipient. Subsequentl\', Barber 
and associates adopted the approach of Mo~acoI and 
preconditioned a series of renal transplant recipients 
with antilymphocyte globulin, cyclosporine, prednisone, 
and azathioprine before infusion of donor bone marrow, 
and demonstrated better graft survival and less acute 
rejection in the bone marrow group [16). Low levels of 
donor chimerism were detected (by peR) in approxi-
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Fig 1. Donor chimt'rism in th~ I't'ripheral blood leukocytes of a lung recipients who received bone marrow infusion. Recipifllt cells were 
st.lined with a primary mouse antibody against human MHC class L then counterstained with fluorescein isothiocyanate (FITC> conjugated 
goat anti-mouse secondary antibody. and analy::ed using an EPICS Elite Flow Cytometer (Couiter Corp, Hialeah, FL). (A) Before transplanta-
tion; (B) 1 month. (0 6 months. and <V) and 9 months after transplantation. The number in the right lower quadrant indicates the percentage 
of donor .:ells. TIu level of chimerism was higher after transplantation. but dwindled with time. 
mately half of the bone marrow group [17]. In another 
study, Kahn and colleagues used high dose total lym-
phoid irradiation (5,400 to 6,000 cGy) to precondition a 
3.0 
• 
2.5 • 
0 Controls 
• 
• 
Bone marrow 
E 2.0 
'" • ·c • v .. ~K • 
.5 J.5 • • 
..c 
•• ::c 
0 < U • ~ 1.0 .00 • • 0 • • y • • • • • ·.0 • 0.5 ... ............... . .. ----- .. -._._-_._. 
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.® • • ~ • eX :& •• C;; .: ill • • cY 0 
0.5 - 2 3 - 5 6-8 9 - II 12 - 14 >P 
Time after transplantation (month) 
Fig 2. Donor cell chimerism detected by flow cytometry in lung re-
cipients. Each circle represents 1 patient. Level below 0.5% is con-
sidered not quantifiable. 
series of heart recipients before heart transplantation and 
intraperitoneal injection of donor bone marrow [18], and 
reported high perioperative death from infection. Of note 
is the fact that in these trials antilymphocytes globulin, 
and radiation had been used to precondition the recipi-
ents before bone marrow infusion. 
The scientific rationale for the current study, which did 
not involve preconditioning of the recipient before bone 
marrow infusion, was based on the discovery by Starzl 
and associates, that donor cells of bone marrow origin 
persisted at low level in peripheral blood, lymphoid 
organs, and skin of long-surviving liver and kidney 
recipients [1, 2]. Based on these observations, we posited 
that donor cell chimerism was perhaps essential for the 
long-term allograft acceptance. Therefore, we hypothe-
sized that augmenting this spontaneously occurring 
event with perioperative donor bone marrow infusion 
may further enhance the acceptance of the graft, espe-
cially of those organs which are not endowed with a large 
quantity of passenger leukocytes. To test this hypothesis, 
in December 1992, we initiated a trial combining donor 
bone marrow infusion with solid organ transplantation, 
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FiS 3 . . f\,1ixed lymphocyte response demonstrahng donor-spl'cifje hy-
poresl'ollsil'elles, lung recipient who ren';t'ed donor bone marrow 
i'lfw;ion. F r('shly isolated recipient peripheral blood leukocytes were 
used as rcspondl7'S. while y-irradiated donor splenocytes and third-
party ce/ls were used as shmulators. TIlt' resl'onse to donor shmula-
tars wa, lowered than that to third-party stimulators. l'-':umbers in 
pl/renthe,e, indicate the 1l'1'c/ of chimerism (by floit' cytometryl. 
without preconditioning of the host [6J. Our aim was to 
augment this de novo phenomenon (chimerism) with the 
hope to reduce the incidence of rejection. 
The preliminary results in lung recipients reported 
herein, indicate that the infusion of unmodified donor 
bone marrow concurrently with lung transplantation is 
safe, and is associated with a trend towards higher level 
of donor cell chimerism, and less donor alloreactivity (by 
MLR assay). Patients in the bone marrow group had less 
requirement for immunosuppression (17% of the BM 
patients required a third drug beside tacrolimus versus 
77% of the controls), lower incidence of obliterative 
bronchiolitis, at least by histologic criteria, than the 
control. One of the limitations of the current study is its 
small sample size and its short follow-up. 
Following our initial report [6J, the transplant group at 
the University of Miami initiated a series of studies using 
single and multiple infusions of donor bone marrow in 
kidney and liver recipients. Our results in lung recipients 
reported herein are in agreement "lith the data on kidney 
recipients from this group. Garcia-Morales and col-
leagues [19] studied 40 kidney recipients who received 
unmodified donor bone marrow infusion, and 100 con-
trols who received kidney alone. Their immunosuppres-
sion protocol induded OKT3 induction therapy, tacroli-
mus, and steroid maintenance therapy, and in some 
patients, mycophenolate mofetil. The authors used a 
newly developed PCR-flow assay (a combination of PCR 
and flow cytometric techniques that detect donor versus 
recipient histocompatibility genes as well as cell surface 
CD epitope markers) to measure donor cell chimerism in 
the recipient's peripheral blood lymphocytes (PBL) and 
bone marrow. The bone marrow recipients have higher 
level of donor chimerism than the controls. Notably, the 
level of donor chimerism (especially CD3+ and CD34+ 
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cells) was 10-fold higher in the bone marrow compart-
ment than in the peripheral blood leukocytes. Immuno-
logically, the bone marrow patients displayed more de-
pressed humoral and cellular immune responses than 
the controls. Recipients who were HLA-DR identical with 
their donors had a high level of chimerism, and no acute 
rejection. In their most recent update (20J, these investi-
gators analyzed the results of 63 cadaveric kidney recip-
ients who received either one (n = 21), or two (n = 42) 
infusions of donor bone marrow and 220 cadaveric kid-
ney recipients who did not receive bone marrow (con-
trols). Although there was no difference in the rates of 
acute rejection, the incidence of chronic rejection in the 
bone marrow group was lower than the control (p < 
0.02). The dose of bone marrow cells and the timing of 
their infusion appear to influence the immune modula-
tion of the hosts. Ricordi and colleagues administered 
donor bone marrow to liver transplant recipients at 
varying schedules after transplantation [21J. Patients re-
ceiving multiple infusion of bone marrow cells had 
significantly longer graft survival than those receiving a 
single infusion. 
Collectively, the results of the present study, along 
with other clinical trials in which donor bone marrow 
cells were infused into recipients of solid organs, suggest 
that donor bone marrow cells may have a modulatory 
effect on the recipient's immune systems, resulting in a 
salutary impact on chronic allograft rejection. While the 
long-term effect of the donor bone marrow infusion in 
lung recipients remains speculative, because of the small 
sample size and relatively short follow-up duration, it is 
conceivable that presence of donor chimerism will en-
hance the acceptance of the graft and reduce the inci-
dence of chronic rejection. Future study with larger 
sample size and longer follow-up will clarify this issue. 
Support in part by the American College of Surgeons Faculty 
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DISCUSSION 
DR JOHN H. CALHOON (San Antonio, TX): My thanks to Dr 
Pham and his colleagues from Pittsburgh on a nicely presented 
series, which should cause us all to reevaluate our lung trans-
plant practice. One question to Dr Pham, about a manuscript 
and presentation that was verv complete and well done, why do 
you think there was a difference in the biopsy incidence of 
obliterative bronchiolitis and the incidence of true bronchiolitis 
obliterans svndrome? 
The other question would center around, where do we go 
from here? '0.'hat do you think the optimum time of donor 
marrow transfusion would be? How would you best augment 
the engrattmen!? V'iould you use cytolytics, consider total lvm-
phoid irradiation. the amount of infusion and/or, as I men-
tioned, its timing? 
I would like to thank Dr Pham and his colleagues for this 
presentation and its contribution to our Society and profession. 
DR FREDERICK L. G ROVER (Denver, CO): I would like to 
particularly thank Dr Pham for his many years of contributions 
to the literature, and to our knowledge in the area of transplan-
tation tolerance and chimerism. I think the most distressing part 
of taking care of lung transplant patients is the 30·'. to 50% 
incidence ot the development of chronic obliterative bronchioli-
tis, which often leads to death, and any light that can be shed in 
this area is obviously very important. 
I was particularly interested in those patients who received 
bone marrow infusion, but failed and later developed e~;dence 
of chronic rejection or obliterative bronchiolitis. Did those spe-
cific patients show decreased reactivity or did they not keep 
sustained chimerism' 
And finallv, how practical is the use of this? What percentage of 
patients will ultimately consent for infusion of the bone marrow? 
Again, thank vou very much. 
DR PHAM: Thank vou very much, Dr Calhoon for your kind 
comments. As I have presented, the incidence of bronchiolitis 
obliterans syndrome which is diagnosed by the clinical criteria is 
lower, but it does not reach statistical significance. As you know, 
bronchiolitis obliterans syndrome, is diagnosed based on the 
reduction in the FEV1• It reflects a global picture of the lung 
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function, and it may be more sensitive than the histological data 
from the transbronchial biopsy, in which sampling errors un-
doubtedly playa role. 
The second question is about the future direction of this study. 
I presented these data as an interim report of a pilot studv to 
assess the safety issue of this procedure. Any time one infuses 
unmodified bone marrow into a patient, especially in a lung 
transplant recipient who has a high number of passenger 
leukocytes, one is concerned about the development of graft-
versus-host disease, which has been reported bv the liver 
transplant group at the Cniversitv of Miami. Therefore, we 
proceed very cautiously. We first show that it can be safely done, 
and then we escalate our conditioning regimen slowly. 
Doctor Camillo Ricordi and associates at the University of Miami 
had shown a survival advantage in liver recipients who received 
multiple infusion of donor bone marrow versus those who received 
single infusion. Based on these data, we currently have initiated the 
multiple bone marrow infusion protocol in lung recipients. 
Another approach is to escalate the conditioning regimen of 
the recipient. However, as one escalates the conditioning regi-
men, one increases the risk of graft-versus-host disease. Re-
cently, Dr Suzanne IIdstad and her associates had demonstrated 
a population of cells, facilitating cells (FC), in the bone marrow 
that facilitate the engraftment of BM stem cells without causing 
graft-versus-host disease. By combining facilitating cells and 
bone marrow stem cells infusion, low dose total bodv irradia-
tion, and conventional immunosuppression, one may achieve 
better bone marrow engraftment with minor risk of graft-
versus-host disease. This protocol is being evaluated at several 
centers by Dr IIdstad and associates. 
I am grateful for Dr Grover's kind comments. Patients who 
have chronic rejection lost their chimerism earlier than others. 
The major difficulty with this protocol was to obtain consent for 
donor bone marrow. In our organ procurement area, we were 
able to get bone marrow from 30')'0 to 50% of cadaveric solid 
organ donors. Outside our area, the rate of getting donor bone 
marrow is less than 5%. I think with more public education, the 
rate of bone marrow donation in cadaveric donors will increase. 
I would like to thank the Society for the opportunity to present 
this paper. 
